Broad Institute wins landmark case over gene editing patents
September 10, 2018 at 11:35 AM EDT
A handful of Massachusetts biotech companies are licensing the CRISPR/Cas9 technology to develop treatments for a range of diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|